TY - JOUR T1 - Localization of Unknown Primary Site with <sup>68</sup>Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1054 LP - 1057 DO - 10.2967/jnumed.116.180984 VL - 58 IS - 7 AU - Yusuf Menda AU - Thomas M. O’Dorisio AU - James R. Howe AU - Michael Schultz AU - Joseph S. Dillon AU - David Dick AU - G. Leonard Watkins AU - Timothy Ginader AU - David L. Bushnell AU - John J. Sunderland AU - Gideon K.D. Zamba AU - Michael Graham AU - M. Sue O’Dorisio Y1 - 2017/07/01 UR - http://jnm.snmjournals.org/content/58/7/1054.abstract N2 - Localization of the site of the unknown primary tumor is critical for surgical treatment of patients presenting with neuroendocrine tumor (NET) with metastases. Methods: Forty patients with metastatic NET and unknown primary site underwent 68Ga-DOTATOC PET/CT in a single-site prospective study. The 68Ga-DOTATOC PET/CT was considered true-positive if the positive primary site was confirmed by histology or follow-up imaging. The scan was considered false-positive if no primary lesion was found corresponding to the 68Ga-DOTATOC–positive site. All negative scans for primary tumor were considered false-negative. A scan was classified unconfirmed if 68Ga-DOTATOC PET/CT suggested a primary, however, no histology was obtained and imaging follow-up was not confirmatory. Results: The true-positive, false-positive, false-negative, and unconfirmed rates for unknown primary tumor were 38%, 7%, 50%, and 5%, respectively. Conclusion: 68Ga-DOTATOC PET/CT is an effective modality in the localization of unknown primary in patients with metastatic NET. ER -